Abbott India Ltd. News and Updates

Name: Latest research reports of Abbott India Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Abbott India Ltd. from all sources in a single place.

Abbott India Ltd.

04 Jul 2025

34280.00

0.01%

Abbott India (BUY): Ascribing valuation in line with its peer GSK

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Novo's oral semaglutide Rybelsus is growing at a robust 173% CAGR over a 3Y period to Rs 4bn, as on MAT MAY'25

Abbott India Ltd. has gained 23.55% in the last 6 Months

Abbott India Ltd.

16 May 2025, 01:18PM

34280.00

0.01%

Abbott India shares gain as Q4 profit jumps 28%; earnings details here

Business Standard

The pharmaceutical company's stock rose as much as 3.86 per cent during the day to 31,500 per share

Abbott India Ltd. has gained 23.55% in the last 6 Months

Abbott India Share Price Gains After Q4 Net Profit, Revenue Rise

NDTV Profit | 16 May 2025, 11:13AM 1 more

Abbott India Ltd.

16 May 2025, 12:00AM

34280.00

0.01%

Sustained improvement across the board

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) revenue grew 12% YoY ahead of most MNCs (avg. growth of ~10% YoY and IPM growth of ~8% YoY in Q4FY25). Abbott’s growth was aided by healthy traction in its own brands along with key brands of Novo Nordisk like Rybelsus and Ryzodeg.

BOB Capital Markets Ltd. increased Buy price target of Abbott India Ltd. to 40128.0 on 04 Jul, 2025.

Abbott India Ltd.

29 Apr 2025

34280.00

0.01%

ERRATA: Abbott India (BUY): Mixtard discard to result in highest-ever EBITDA margin

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Novo Nordisk insulin brand outgo to result in 330 bps and 670 bps increase in EBITDA margin to 30.9% and 34.9% for FY26E and FY27E

Abbott India Ltd. has gained 23.55% in the last 6 Months

Abbott India Ltd.

11 Apr 2025

34280.00

0.01%

[Initiation] Abbott India (BUY): A safe pick amidst tariff woes

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Sales expected to reach USD 1bn, driven by industry-leading MR productivity of Rs 14.9mn by FY27E from Rs 11.5mn in FY24

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

06 Feb 2025

34280.00

0.01%

Abbott India gains 10% in 2 days after posting healthy Q3 show; Details

Business Standard

The company's Q3 profit increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore

Abbott India Ltd. has an average target of 34719.50 from 4 brokers.

Abbott India Ltd.

06 Feb 2025

34280.00

0.01%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

06 Feb 2025

34280.00

0.01%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock

Abbott India Ltd. has gained 23.55% in the last 6 Months

Abbott India Ltd.

19 Dec 2024

34280.00

0.01%

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

Business Standard

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%